Can't find Pneumovax 23? Learn about alternative pneumococcal vaccines like Prevnar 20 and Vaxneuvance, how they compare, and which one might be right for you.
Your doctor recommended Pneumovax 23, but the pharmacy is out of stock. Now what? Before you panic or skip the vaccination altogether, know this: there are other pneumococcal vaccines available, and one of them may be a good fit for you.
In this guide, we'll explain what Pneumovax 23 does, how it works, and walk you through the real alternatives so you can have an informed conversation with your doctor.
Pneumovax 23 (also called PPSV23) is a vaccine made by Merck that protects against 23 types of Streptococcus pneumoniae bacteria. These bacteria can cause serious — sometimes life-threatening — infections including:
Pneumovax 23 is recommended for adults 65 and older, adults 19–64 with certain chronic conditions or risk factors, and children 2 and older who are at high risk for pneumococcal disease.
Pneumovax 23 is a polysaccharide vaccine. It contains purified sugar-like molecules (polysaccharides) from the outer coating of 23 different pneumococcal bacteria types. When these polysaccharides are injected into your body, your immune system recognizes them as foreign and produces antibodies against them.
These antibodies then stand guard, ready to fight off real pneumococcal bacteria if you're ever exposed. The protection typically develops within 2–3 weeks after vaccination.
One important detail: polysaccharide vaccines primarily stimulate B cells directly (a "T-cell independent" response). This means the immune memory isn't as long-lasting as conjugate vaccines, which is why some patients need a booster dose after 5 years.
If you can't find Pneumovax 23, here are the main alternatives to discuss with your healthcare provider:
What it covers: 20 pneumococcal serotypes
How it works: Prevnar 20 is a conjugate vaccine, meaning the polysaccharides are attached to a carrier protein. This triggers a stronger, longer-lasting immune response that involves both B cells and T cells. The result is better immune memory compared to polysaccharide vaccines like Pneumovax 23.
Who it's for: The CDC recommends Prevnar 20 as an option for adults 19 and older who have not previously received a pneumococcal conjugate vaccine, or who need to complete their pneumococcal vaccine series. For many adults, a single dose of Prevnar 20 can replace the need for both a conjugate vaccine and Pneumovax 23.
Key advantage: One dose may be all you need. If you haven't received any pneumococcal vaccines yet, Prevnar 20 alone may provide sufficient protection without needing a follow-up dose of Pneumovax 23.
Limitation: It covers 20 serotypes compared to Pneumovax 23's 23. However, the 3 serotypes unique to Pneumovax 23 cause a relatively small percentage of pneumococcal disease in adults.
Approximate cost: $250–$350 per dose without insurance. Covered by most insurance plans and Medicare Part B at no cost.
What it covers: 15 pneumococcal serotypes
How it works: Like Prevnar 20, Vaxneuvance is a conjugate vaccine that produces strong, long-lasting immunity. It also uses a carrier protein to enhance the immune response.
Who it's for: Adults 19 and older. However, because it covers fewer serotypes, the ACIP recommends following Vaxneuvance with a dose of Pneumovax 23 (at least 8 weeks later, or at least 1 year later for certain immunocompromised patients) to extend protection to additional serotypes.
Key consideration: If you're having trouble finding Pneumovax 23 now, starting with Vaxneuvance might not solve your problem entirely — you'd still need Pneumovax 23 later. However, getting Vaxneuvance now gives you immediate protection against 15 serotypes while you wait for Pneumovax 23 to become available.
Approximate cost: $250–$330 per dose without insurance. Also covered by most insurance and Medicare Part B.
What it covers: 13 pneumococcal serotypes
How it works: Another conjugate vaccine, similar in mechanism to PCV15 and PCV20 but covering fewer serotypes.
Current status: Prevnar 13 has been largely replaced by Prevnar 20 and Vaxneuvance in current ACIP recommendations for adults. It is still used in pediatric vaccination schedules. Your doctor is unlikely to recommend it as a first choice for adults in 2026, but it may still be available in some settings.
The right choice depends on several factors:
For many patients who haven't received any pneumococcal vaccine yet, Prevnar 20 is the most practical alternative — it's one shot, it's widely available, and it provides strong, lasting protection against 20 serotypes.
Not being able to find Pneumovax 23 is frustrating, but it doesn't mean you have to go without protection. Talk to your doctor about whether Prevnar 20, Vaxneuvance, or another approach is right for you. The most important thing is that you get vaccinated against pneumococcal disease — the specific vaccine matters less than making sure you're protected.
Use Medfinder to check availability for Pneumovax 23 and other pneumococcal vaccines near you. And for more about the current supply situation, read our Pneumovax 23 shortage update for 2026.
You focus on staying healthy. We'll handle the rest.
Try Medfinder Concierge FreeMedfinder's mission is to ensure every patient gets access to the medications they need. We believe this begins with trustworthy information. Our core values guide everything we do, including the standards that shape the accuracy, transparency, and quality of our content. We’re committed to delivering information that’s evidence-based, regularly updated, and easy to understand. For more details on our editorial process, see here.
%2C%20Color%3DOriginal.png)
